What are the short-term annual cost savings associated with kidney transplantation?
Cost savings
Cost-group
Finite mixture model
High-cost
Kidney transplantation
Journal
Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476
Informations de publication
Date de publication:
03 May 2022
03 May 2022
Historique:
received:
26
01
2022
accepted:
09
04
2022
entrez:
3
5
2022
pubmed:
4
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Kidney transplantation (KT) is often reported in the literature as associated with cost savings. However, existing studies differ in their choice of comparator, follow-up period, and the study perspective. Also, there may be unobservable heterogeneity in health care costs in the patient population which may divide the population into groups with differences in cost distributions. This study estimates the cost savings associated with KT from a payer perspective and identifies and characterizes both high and low patient cost groups. The current study was a population-based retrospective before-and-after study. The timespan involved at most three years before and after KT. The sample included end-stage kidney disease patients in Nova Scotia, a province in Canada, who had a single KT between January 1, 2011, and December 31, 2018. Each patient served as their control. The primary outcome measure was total annual health care costs. We estimated cost savings using unadjusted and adjusted models, stratifying the analyses by donor type. We quantified the uncertainty around the estimates using non-parametric and parametric bootstrapping. We also used finite mixture models to identify data-driven cost groups based on patients' pre-transplantation annual inpatient costs. The mean annual cost savings per patient associated with KT was $19,589 (95% CI: $14,013, $23,397). KT was associated with a 24-29% decrease in mean annual health care costs per patient compared with the annual costs before KT. We identified and characterized patients in three cost groups made of 2.9% in low-cost (LC), 51.8% in medium-cost (MC) and 45.3% in high-cost (HC). Cost group membership did not change after KT. Comparing costs in each group before and after KT, we found that KT was associated with 17% mean annual cost reductions for the LC group, 24% for the MC group and 26% for the HC group. The HC group included patients more likely to have a higher comorbidity burden (Charlson comorbidity index ≥ 3). KT was associated with reductions in annual health care costs in the short term, even after accounting for costs incurred during KT.
Sections du résumé
BACKGROUND
BACKGROUND
Kidney transplantation (KT) is often reported in the literature as associated with cost savings. However, existing studies differ in their choice of comparator, follow-up period, and the study perspective. Also, there may be unobservable heterogeneity in health care costs in the patient population which may divide the population into groups with differences in cost distributions. This study estimates the cost savings associated with KT from a payer perspective and identifies and characterizes both high and low patient cost groups.
METHOD
METHODS
The current study was a population-based retrospective before-and-after study. The timespan involved at most three years before and after KT. The sample included end-stage kidney disease patients in Nova Scotia, a province in Canada, who had a single KT between January 1, 2011, and December 31, 2018. Each patient served as their control. The primary outcome measure was total annual health care costs. We estimated cost savings using unadjusted and adjusted models, stratifying the analyses by donor type. We quantified the uncertainty around the estimates using non-parametric and parametric bootstrapping. We also used finite mixture models to identify data-driven cost groups based on patients' pre-transplantation annual inpatient costs.
RESULTS
RESULTS
The mean annual cost savings per patient associated with KT was $19,589 (95% CI: $14,013, $23,397). KT was associated with a 24-29% decrease in mean annual health care costs per patient compared with the annual costs before KT. We identified and characterized patients in three cost groups made of 2.9% in low-cost (LC), 51.8% in medium-cost (MC) and 45.3% in high-cost (HC). Cost group membership did not change after KT. Comparing costs in each group before and after KT, we found that KT was associated with 17% mean annual cost reductions for the LC group, 24% for the MC group and 26% for the HC group. The HC group included patients more likely to have a higher comorbidity burden (Charlson comorbidity index ≥ 3).
CONCLUSIONS
CONCLUSIONS
KT was associated with reductions in annual health care costs in the short term, even after accounting for costs incurred during KT.
Identifiants
pubmed: 35505433
doi: 10.1186/s12962-022-00355-2
pii: 10.1186/s12962-022-00355-2
pmc: PMC9063122
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20Informations de copyright
© 2022. The Author(s).
Références
Clinicoecon Outcomes Res. 2012;4:145-55
pubmed: 22719214
Kidney Med. 2020 Nov 11;3(1):20-30.e1
pubmed: 33604537
Ann Transplant. 2019 Jul 02;24:393-400
pubmed: 31263093
Stat Med. 2019 Jan 30;38(2):210-220
pubmed: 30207407
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1197-1203
pubmed: 30021819
Am J Transplant. 2004 Apr;4(4):569-73
pubmed: 15023149
Nat Rev Nephrol. 2014 Nov;10(11):644-52
pubmed: 25157840
Prog Transplant. 2014 Sep;24(3):257-62
pubmed: 25193726
Clin Kidney J. 2018 Apr;11(2):283-288
pubmed: 29644072
Med Care. 2015 Sep;53(9):e65-72
pubmed: 23703645
Nephrol Dial Transplant. 2015 Oct;30(10):1726-34
pubmed: 26071229
Thorax. 2016 Mar;71(3):267-75
pubmed: 26732738